Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT03790332 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT03790332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03790332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 1/2
Overall status
Completed
Start date
November 19, 2018
Completion date
October 9, 2025
Enrollment
59 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease